Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
It was examined that the BDC 2.5-like T cell response in NOD mice by sorting and analyzing single cells with I-Ag7 tetramers displaying BDC 2.5 peptide mimotopes with either a negative charge (HHPIWARMDA; hereafter referred to as 2.5mi) or no charge at P9 (G or Q, named P9G and P9Q thereafter, HHPIWARMG/QA). The sequencing of individual TCR segments revealed an increase of negative residues in the CDR3β N-terminal region from cells sorted with P9Q or P9G tetramers (16/31, 52%) as compared with cells sorted with P9D tetramers (5/23, 21%). The latter frequency was comparable to the normal frequency of negative charges found in all purified CD4+ CDR3β sequences in NOD mice. The negative charges found in the CDR3β of the P9Q and P9G populations were encoded by N additions or deletions, suggesting an antigen-driven process. This belief was also supported by the fact that P9G or P9Q tetramer–positive cells were found in higher numbers in the periphery than in the thymus and that over time, the population expanded early (3–4 weeks), then contracted (6–12 weeks) to reexpand later, especially in diabetic animals. In addition, the BDC 2.5 9Q/9G reactive TCR populations were found, up until week twelve, to be larger than the corresponding BDC 2.5 9D populations.
There are currently no customer reviews or questions for Mouse anti-2.5mi 9G T cell receptor (#63), pCDTCR1 (TCR-YC0033). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
